Yosemite is an oncology-focused venture capital firm founded by Reed Jobs in 2023, spun out of the Emerson Collective. The firm invests in early-stage cancer-focused companies and provides philanthropic grants to academic researchers, aiming to make cancer non-lethal within our lifetime.
62% of their portfolio is in Healthcare. Deal activity increased 267% year-over-year (11 deals in the last 12 months). Average disclosed round size is $51.2M (across 12 rounds with reported amounts).
Portfolio
13
Fund Size
$200M
Top Stage
Series A
Last 12 Mo
11
Team
DM
Daniel McHugh
Lead of the investment team
MB
Matt Bettonville
Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
16 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| TTurquoise | Series C | $40M | Mar 2026 |
 Turquoise Health | Series C | $40M | Mar 2026 |
 Ten63 | Unknown | — | Feb 2026 |
 Solve Therapeutics | Unknown | $120M | Jan 2026 |
 Chai Discovery | Series B | $130M | Dec 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Sage | Series A | $20M | Oct 2025 |
 Fourier | Seed | $8.4M | Oct 2025 |
 Sage Care | Unknown | $20M | Oct 2025 |
 Daymark Health | Series A | $20M | Sep 2025 |
| DDaymark | Series A | $20M | Sep 2025 |
| Chai Discovery | Series A | — | Aug 2025 |
| DDaymark | Seed | $11.5M | Apr 2025 |
 Tune Therapeutics | Series D | — | Jan 2025 |
 SHINOBI THERAPEUTICS | Series A | — | Aug 2024 |
 Azalea Therapeutics | Series A | $65M | — |
Top Co-Investors
SV Angel4 shared
General Catalyst3 shared
Oak HC/FT3 shared
Alexandria Venture Investments3 shared
Maverick Ventures3 shared
Oncology Ventures3 shared
Menlo Ventures2 shared
Dimension2 shared
OpenAI Startup Fund2 shared
Neo2 shared
Thrive Capital2 shared
Metrodora Ventures2 shared
Liquid 2 Ventures2 shared
AME Cloud Ventures2 shared
The Blue Venture Fund2 shared
Healthier Capital2 shared
B Capital2 shared
SymBiosis2 shared
Abingworth LLP2 shared
Ally Bridge Group2 shared
Last updated: 8 September 2026